ARK Genomic Revolution ETF vs Enovix Corporation — how do they compare? ARK Genomic Revolution ETF trades at $44.51, while Enovix Corporation trades at $4.83 (market cap $1.06B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | ENVX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $13.19 |
52-Week Low | $24.02 | $3.68 |
Market Cap | — | $1.06B |
Enterprise Value | — | $1.07B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENVX trades at $4.92, up 6.03% in the last 24 hours, with a bullish technical signal despite negative profitability. Recent earnings beats and the appointment of a former Apple executive as COO highlight operational progress. The stock shows strong analyst support with a consensus price target of $12.38, though cash flow remains negative as the company scales production.
Outlook is cautiously optimistic given high growth potential in advanced battery technology, but significant execution risks and persistent losses require careful monitoring. The stock offers upside if production ramps successfully, but volatility may persist near-term.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →